Literature DB >> 19212213

Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy.

Justin L Sewell1, Kristine M Stick, Alexander Monto.   

Abstract

Among hepatitis C patients, lack of cirrhosis and sustained virologic response (SVR) reduce the risk of hepatocellular carcinoma (HCC). Japanese studies document multiple cases of HCC among these patients, but only one case has been reported outside of Asia. We identified five patients with hepatitis C in our university-based hepatology practice who developed HCC despite SVR and lack of cirrhosis on their pretreatment liver biopsy. At the time of HCC diagnosis, two remained noncirrhotic, one had clearly progressed to cirrhosis, and two lacked repeat histology. We present these patients in a case series format and discuss several important implications of their cases. Physicians often base screening and treatment decisions on an initial liver biopsy performed years earlier. As fibrosis may advance, and because SVR and lack of cirrhosis do not fully protect against HCC, future study should further evaluate the risk of HCC among hepatitis C patients after sustained virologic response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212213      PMCID: PMC2744965          DOI: 10.1097/MEG.0b013e32831101b7

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  19 in total

1.  Management of hepatocellular carcinoma.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2005-11       Impact factor: 17.425

2.  De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.

Authors:  Kevin S Sieja; Gregory T Everson
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

3.  Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.

Authors:  Disaya Chavalitdhamrong; Tawesak Tanwandee
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

4.  Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

Authors:  Sigal Kremer-Tal; Goutham Narla; Yingbei Chen; Eldad Hod; Analisa DiFeo; Steven Yea; Ju-Seog Lee; Myron Schwartz; Swan N Thung; Isabel M Fiel; Michaela Banck; Eran Zimran; Snorri S Thorgeirsson; Vincenzo Mazzaferro; Jordi Bruix; John A Martignetti; Josep M Llovet; Scott L Friedman
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

5.  Occult viral hepatitis and noncirrhotic hepatocellular carcinoma.

Authors:  Stuart C Gordon
Journal:  Am J Gastroenterol       Date:  2005-08       Impact factor: 10.864

6.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

Authors:  C Cammà; M Giunta; P Andreone; A Craxì
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

7.  Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Authors:  H Tanaka; H Tsukuma; A Kasahara; N Hayashi; H Yoshihara; M Masuzawa; T Kanda; T Kashiwagi; A Inoue; M Kato; A Oshima; Y Kinoshita; T Kamada
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

8.  Long-term follow-up study of sustained biochemical responders with interferon therapy.

Authors:  M Shindo; K Hamada; Y Oda; T Okuno
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

9.  Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis.

Authors:  Kouji Miyagawa; Chouhei Sakakura; Susumu Nakashima; Tetsuji Yoshikawa; Shuichi Kin; Yuenn Nakase; Kosei Ito; Hisakazu Yamagishi; Hiroshi Ida; Shujiro Yazumi; Tsutomu Chiba; Yoshiaki Ito; Akeo Hagiwara
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

10.  A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.

Authors:  Tanios Bekaii-Saab; Nita Williams; Christoph Plass; Miguel Villalona Calero; Charis Eng
Journal:  BMC Cancer       Date:  2006-12-06       Impact factor: 4.430

View more
  7 in total

1.  Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?

Authors:  Gino S Albines; Alicia Mesa; Nelson Fuentes-Martínez; Ramón Pérez; Julieta Fernández-Molina; Manuel Rodríguez; María Varela
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

2.  Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C.

Authors:  Shinji Takashimizu; Sei-Ichiro Kojima; Junko Nagata; Yasuhiro Nishizaki; Tatehiro Kagawa; Koichi Shiraishi; Tetsuya Mine; Jun-Ichi Kaneko; Norihiro Kokudo; Norihito Watanabe
Journal:  Clin J Gastroenterol       Date:  2011-03-24

3.  Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals.

Authors:  Fabian Finkelmeier; Georg Dultz; Kai-Henrik Peiffer; Bernd Kronenberger; Franziska Krauss; Stefan Zeuzem; Christoph Sarrazin; Johannes Vermehren; Oliver Waidmann
Journal:  Liver Cancer       Date:  2018-03-01       Impact factor: 11.740

4.  Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.

Authors:  Ryan A Hlady; Rochelle L Tiedemann; William Puszyk; Ivan Zendejas; Lewis R Roberts; Jeong-Hyeon Choi; Chen Liu; Keith D Robertson
Journal:  Oncotarget       Date:  2014-10-15

5.  Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.

Authors:  Khai-Jing Ng; Chih-Wei Tseng; Ting-Tsung Chang; Shinn-Jia Tzeng; Yu-Hsi Hsieh; Tsung-Hsing Hung; Hsiang-Ting Huang; Shu-Fen Wu; Kuo-Chih Tseng
Journal:  Clin Interv Aging       Date:  2016-08-01       Impact factor: 4.458

6.  Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.

Authors:  Annie Y Chen; Marija Zeremski; Ranjit Chauhan; Ira M Jacobson; Andrew H Talal; Tomasz I Michalak
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

7.  HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.

Authors:  Angelo Alves de Mattos; Patrícia dos Santos Marcon; Fernanda Schild Branco de Araújo; Gabriela Perdomo Coral; Cristiane Valle Tovo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-12       Impact factor: 1.846

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.